Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Change of indications for phase II trials of KOS-862

June 29, 2004

XL-119 enters phase III trial in bile duct cancer

June 29, 2004

Target enrollment met in phase III study of Campath for B-CLL

June 29, 2004

IND accepted for phase II trials of Aplidin

June 29, 2004

Two series of MEK/c-Src kinase inhibitors claimed by AstraZeneca

June 29, 2004

New antiangiogenic agents in early development at Bayer

June 28, 2004

New phase II study of talabostat in CLL

June 28, 2004

Positive interim results from phase II trial of FK-228 in CTCL and PTCL

June 28, 2004

Synthetic adrenal steroid hormones protect from chemotherapy or radiation-induced myelodepression

June 28, 2004

Merck & Co. and Vertex collaborate on development of VX-680

June 28, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...